Combined Antiplatelet and Anticoagulation Therapy in Diabetes and Cardiovascular Disease Studied in the COMPASS Trial
March 28, 2020—Findings from a prespecified analysis of COMPASS trial on the role of combination antiplatelet and anticoagulation therapy in diabetes and cardiovascular disease were presented by Deepak L. Bhatt, MD, in the virtual conference of the American College of Cardiology’s Annual Scientific Session together with the World Congress of Cardiology (ACC.20/WCC).
TAILOR-PCI Trial Evaluates Genetic Testing to Guide Post-PCI Antiplatelet Therapy
March 28, 2020—The American College of Cardiology (ACC) announced that findings from the TAILOR-PCI international clinical trial to test the effectiveness of genetic testing to guide which antiplatelet medication was given to patients after percutaneous coronary intervention (PCI)—were presented by coprincipal investigator Naveen L. Pereira, MD, at the ACC's Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC), which is being held this year as a virtual conference.
Study Shows Similar 1-Year Outcomes for Women and Men Treated With OrbusNeich's Combo DES
March 21, 2020—Online in Catheterization and Cardiovascular Interventions, Jaya Chandrasekhar, MBBS, et al published findings from an examination of sex differences in 1‐year outcomes with the Combo drug-eluting stent (OrbusNeich).
Keystone Heart's TriGuard 3 Cerebral Embolic Protection Device Receives CE Mark Approval for Use in Transcatheter Heart Procedures
March 10, 2020—Keystone Heart Ltd., a Venus Medtech Company, announced European CE Mark approval for the TriGuard 3 cerebral embolic protection device, which is designed to cover and protect all three major cerebral aortic arch vessels during transcatheter aortic valve replacement (TAVR) and other transcatheter heart procedures.
Study Shows Benefits of PVADs Versus IABPs for PCI in High-Risk Patients
March 4, 2020—Abiomed, Inc. announced the publication of a study of 21,848 nonemergent, high-risk patients who underwent percutaneous coronary intervention (PCI) with either a percutaneous ventricular assist device (PVAD), including the company’s Impella heart pumps, or an intra-aortic balloon pump (IABP).
Meta-Analysis Compares DES and CABG for Left Main Coronary Artery Disease
March 2, 2020—Findings from a meta-analysis comparing percutaneous coronary intervention (PCI) with drug-eluting stents (DESs) versus coronary artery bypass grafting (CABG) for patients with left main coronary artery disease (LMCAD) were published by Yousif Ahmad, MD, et al online ahead of print in European Heart Journal (EHJ).
Pooled Analysis Supports Diagnostic Performance of CathWorks' Angiogram-Derived Fractional Flow Reserve
February 17, 2020—A pooled analysis of five prospective cohort studies sought to assess the diagnostic performance of FFRangio (CathWorks), an angiogram-derived fractional flow reserve (FFR) technology.
Philips’ DEFINE GPS Trial Will Assess Outcomes of PCI Guided by an Integrated Platform of iFR and Angiogram
February 11, 2020—Royal Philips announced a new randomized controlled trial to assess patient outcomes after receiving percutaneous coronary intervention (PCI) guided by Philips’ coregistration platform (which combines data of instant wave-free ratio (iFR) measurement and angiography) compared with the standard of care treatment guided by angiography alone.
Medtronic Begins SPYRAL DYSTAL Pilot Study of Renal Denervation in Hypertensive Patients
February 4, 2020—Medtronic announced it will begin enrollment in a pilot study evaluating the safety and efficacy of the Symplicity Spyral renal denervation (RDN) system using a targeted procedural approach with a reduced number of radiofrequency (RF) ablations.
Study From CathPCI Registry Analyzes Trends in Usage and Outcomes of Coronary Atherectomy
January 24, 2020—Nirat Beohar, MD, et al conducted a study that sought to assess the trends in usage, interhospital variability, and outcomes with coronary atherectomy (CA) among patients undergoing percutaneous coronary intervention (PCI).
Three-Year Findings Published for Mortality of Repeat Revascularizations in the EXCEL Trial
January 15, 2020—The 3-year findings from an investigation to determine the incidence and impact on mortality of repeat revascularization after index percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) for left main coronary artery disease (LMCAD) in the EXCEL trial were published by Gennaro Giustino, MD, et al in Journal of the American College of Cardiology (JACC): Cardiovascular Interventions.
Study Confirms Prognostic Value of the GRACE Discharge Score for PCI in Stable CAD Patients
January 10, 2020—Xue Yan Zhao, MD, published findings from a study to assess the predictive value of the Global Registry of Acute Coronary Events (GRACE) discharge score for patients with stable coronary artery disease (CAD) after percutaneous coronary intervention (PCI).
Massive Pulmonary Embolism: The Role of Mechanical Circulatory Support
Use of mechanical circulatory support appears to be feasible in a subset of patients with pulmonary embolism, but expertise in placement and postprocedural management is critical.
By Catalin Toma, MD, Michael Jolly, MD, and Christopher Huff, MD
US Device Guide
This Device Guides offers a searchable, comprehensive listing of the available interventional cardiology devices in the United States.
European Device Guide
This Device Guides offers a searchable, comprehensive listing of the available interventional cardiology devices in Europe.